NCT00253422View on ClinicalTrials.gov

Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors

PHASE3CompletedINTERVENTIONAL

Enrollment

698

Participants

Timeline

Start Date

March 26, 2004

Primary Completion Date

November 28, 2022

Study Completion Date

November 28, 2022

Conditions

Breast Cancer

Interventions

DRUG

Anastrozole

This may be Anastrazole OR a placebo

DRUG

Exemestane

DRUG

Fulvestrant

Trial Locations (2)

SW3 6JJ

Royal Marsden - London, London

SM2 5NG

Institute Of Cancer Research, Sutton

All Listed Sponsors

collaborator

Royal Marsden NHS Foundation Trust

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER

NCT00253422 - Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors | Biotech Hunter | Biotech Hunter